Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
PR-001 by Prevail Therapeutics for Gaucher Disease Type I: Likelihood of Approval
PR-001 is under clinical development by Prevail Therapeutics and currently in Phase II for Gaucher Disease Type I. According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's PR-001?
PR-001 is a gene therapy commercialized by Eli Lilly and Co, with a leading Phase II program in Parkinson's Disease....